Soteria Biotherapeutics

📍 San Mateo, United States🗓 Founded 2018👥 6 employees💰 Last funded Jul 2018
Biotechnology Research🌐 soteriabiotherapeutics.com
Website LinkedIn
Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Mateo, California.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in Soteria Biotherapeutics?
Soteria Biotherapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Soteria Biotherapeutics last raise funding?
The most recent investment in Soteria Biotherapeutics recorded on gritt.io was in July 2018.
When was Soteria Biotherapeutics founded?
Soteria Biotherapeutics was founded in 2018.
What industry is Soteria Biotherapeutics in?
Soteria Biotherapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Soteria Biotherapeutics based?
Soteria Biotherapeutics is headquartered in San Mateo, United States.